An official website of the United States government
Home
Name
Carfilzomib
Alternate Names
Kyprolis
Abbreviations
None
Category
Chemotherapy
Subcategory
Proteasome inhibitor
NSC Number
None
Primary Site
Multiple myeloma
Histology
None
Remarks
September 4, 2020: FDA has approved Kyprolis (carfilzomib) and Darzalex (daratumumab) in combination with dexamethasone for adult patients with relapsed or refractory multiple myeloma who have received one to three lines of therapy.
July 20, 2012 the FDA approved Kyprolis under the accelerated approval program for the treatment of multiple myeloma.
July 20, 2012 the FDA approved Kyprolis under the accelerated approval program for the treatment of multiple myeloma.
Coding
This drug should be coded
